The global Acute Ischemic Stroke (AIS) market is estimated to be valued at US$ 8,517.0 million in 2021 and is expected to exhibit a CAGR of 4.0% over the forecast period (2021-2028), as highlighted in a new report published by Coherent Market Insights.
Market Overview:
The Acute Ischemic Stroke (AIS) market refers to the market for products and therapies used in the diagnosis, treatment, and management of acute ischemic stroke. This includes medical devices such as clot retrieval devices, imaging systems, and diagnostic tools, as well as pharmaceuticals used for thrombolysis and neuroprotection. With the increasing prevalence of stroke cases globally, there is a growing demand for effective and efficient stroke management solutions.
Market Dynamics:
The market dynamics of the Acute Ischemic Stroke (AIS) market are driven by two key factors. Firstly, the increasing prevalence of stroke cases worldwide is leading to a higher demand for effective treatment options. The aging population and changing lifestyles contribute to the rising incidence of strokes. Secondly, there is a growing awareness among individuals and healthcare professionals regarding the importance of early diagnosis and prompt treatment for stroke to minimize long-term disabilities and improve outcomes. This has resulted in increased investments in research and development of innovative treatment options for acute ischemic stroke.
SWOT Analysis:
Strength:
The Acute Ischemic Stroke (AIS) market has a high growth potential, with a projected compound annual growth rate (CAGR) of 4.0% from 2021 to 2028. This growth is driven by factors such as the increasing prevalence of AIS and advancements in medical treatments for the condition. Key players in the market, such as F. Hoffmann-La Roche AG and Boehringer Ingelheim, have a strong presence and expertise in AIS treatment.
Weakness:
One weakness in the AIS market is the high cost associated with the treatment and management of the condition. This can limit access to effective therapies for patients without adequate healthcare coverage. Another weakness is the limited awareness and understanding of AIS among the general population, leading to delayed diagnosis and treatment.
Opportunity:
There are opportunities for growth in the AIS market, driven by the increasing investment in research and development activities focused on developing new and improved treatment options. Additionally, the rising geriatric population, which is more susceptible to AIS, presents a significant opportunity for market expansion.
Threats:
One major threat to the AIS market is the stringent regulatory requirements and approval processes for new treatment options. This can lead to significant delays and increased costs for market players. Another threat is the presence of substitute treatment options, such as alternative medicine and non-pharmacological interventions, which may compete with traditional pharmaceutical treatments.
Key Takeaways:
The Global Acute Ischemic Stroke (AIS) Market Demand is expected to witness high growth, exhibiting a CAGR of 4.0% over the forecast period. This growth is attributed to factors such as the increasing prevalence of AIS and advancements in medical treatments.
Key players operating in the AIS market include F. Hoffmann-La Roche AG, Boehringer Ingelheim, Bayer AG, Pfizer Inc., Biogen, Daiichi Sankyo, Bristol-Myers Squibb, Johnson & Johnson, AstraZeneca, SanBio, and Athersys Inc.These companies have a strong presence and expertise in AIS treatment, contributing to market growth.
